COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency. Issue 6 (December 2021)

• Record Type: Journal Article
• Authors: Ponsford, Mark J.; Shillitoe, Benjamin M.J.; Humphreys, Ian R.; Gennery, Andrew R.; Jolles, Stephen
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 21:Issue 6(2021)
• Publication Date: 2021-12
• Subjects: Bruton's tyrosine kinase -- convalescent plasma therapy -- immunoglobulin replacement therapy -- secondary antibody deficiency -- X-linked agammaglobulinemia; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000792
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: The clinical outcomes from COVID-19 in monogenic causes of predominant antibody deficiency have pivotal implications for our understanding of the antiviral contribution of humoral immunity. This review summarizes the lessons learned from COVID-19 infection in X-linked agammaglobulinemia (XLA) due to genetic defects in Bruton's tyrosine kinase (BTK). Recent findings: Key molecular pathways underlying the development of severe COVID-19 are emerging, highlighting the possible contribution of BTK to hyperinflammation. SARS-CoV-2 specific T-cell responses and complement activation appear insufficient to achieve viral clearance in some B-cell deficient individuals. Whilst appearing efficacious in this group, use of convalescent plasma has been recently associated with the evolution of viral escape variants. Early data suggests individuals with XLA can mount a viral-specific T-cell vaccine response, however, the clinical significance of this is still emerging. Summary: In contrast to reports made early in the pandemic, we show XLA patients remain susceptible to severe disease. Persistent infection was common and is likely to carry a significant symptom burden and risk of novel variant evolution. COVID-19 infection in this vulnerable, antibody deficient group due to genetic, therapeutic or disease causes may require prompt and specific intervention for both patient and societal benefit.